Long-term complete responses after (131)I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma

We present the long-term results of 18 chemotherapy relapsed indolent (N=12) or transformed (N=6) NHL patients of a phase II anti-CD20 (131)I-tositumomab (Bexxar®) therapy study. The biphasic therapy included two injections of 450 mg unlabelled antibody combined with (131)I-tositumomab once as dosim...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchegger, F, Antonescu, C, Delaloye, A Bischof, Helg, C, Kovacsovics, T, Kosinski, M, Mach, J-P, Ketterer, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361356/
https://www.ncbi.nlm.nih.gov/pubmed/16685263
http://dx.doi.org/10.1038/sj.bjc.6603166

Ejemplares similares

Ejemplares similares